Actelion Pharmaceuticals US, Inc.
Hopewell Township, NJ Part of Janssen Biotech Inc.
- UEI
- H5BMHLMMNA28
- CAGE
- 33TN9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Janssen Biotech Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Janssen Biotech Inc. · Horsham, PA
NVYMGFA53MN7
-
Parent
Janssen Biotech Inc. · Horsham, PA
NVYMGFA53MN7
- SAM.gov registration date
- Physical address
- 1125 Trenton Harbourton Rd, Titusville, NJ 08560, USA
- Website
- jnj.com
- Founded
- 1886
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $21,476 |
| FY2026 | $1,165,142 |
| FY2025 | $1,361,413 |
| FY2024 | $2,697,244 |
| FY2023 | $1,817,443 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Justice | $921,090 | |
| 2 | Department of Veterans Affairs | $265,528 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ortho Biotech Products, LP | Horsham, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Curascript SD Specialty Distribution | Lake Mary, FL | 456110 Pharmacies and Drug Retailers |
| Centocor Ortho Biotech Inc. | Horsham, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Ferring Pharmaceuticals Inc. | Parsippany-Troy Hills, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Actelion Pharmaceuticals US, Inc., a subsidiary of Janssen Biotech Inc., manufactures and distributes specialty pharmaceutical products for rare diseases—primarily pulmonary arterial hypertension treatments—to federal healthcare institutions as a large for-profit pharmaceutical manufacturer competing full-and-open without small business certifications. The vendor operates as a prime contractor exclusively, holding no subcontract positions across its 1,974 recent federal awards.
Actelion's product portfolio centers on a narrow set of branded and generic pulmonary arterial hypertension medications: Uptravi (selexipag), Opsumit (ambrisentan), Tracleer (bosentan), Veletri (epoprostenol), Adempas (riociguat), Zavesca (miglustat), Ventavis (iloprost), Opsynvi (ambrisentan/tadalafil), and Tyvaso (treprostinil). Representative work includes recurring monthly delivery orders from Federal Correctional Institution Fort Worth and Federal Medical Center Carswell ranging from $12,540 to $100,480 for Uptravi and Opsumit supplies; a $602.9 million bulk order from Veterans Integrated Service Network 20 for selexipag (February 2024, completed February 2025); and a $406.5 million order from Veterans Integrated Service Network 20 for Uptravi 800 microgram tablets (October 2025). Manufacturing and distribution occur from headquarters in Titusville, New Jersey, with subordinate distribution nodes in Lake Mary, Florida and Bartlett, Tennessee serving federal facilities nationwide.
Customer concentration is extreme and Veterans Affairs–dominated. The top five funding agencies by potential value account for 68 percent of combined potential dollars, anchored by Veterans Integrated Service Network 12 with $746.5 million across 68 awards—a single customer generating approximately 65 percent of all potential value in the source. The Department of Veterans Affairs Veterans Health Administration, in aggregate, funds the vast majority of Actelion's federal work. The Department of Justice Federal Bureau of Prisons (Federal Correctional Institution Fort Worth, Federal Medical Center Carswell, Federal Correctional Complex Terre Haute, and Federal Correctional Complex Florence) represents the second-tier customer base, with dozens of small monthly delivery orders for inmate pharmaceutical supply. The 38 percent of awards covered by the top five customers by count spread across dozens of Veterans Integrated Service Networks and correctional institutions, each placing small, recurring orders; the 68 percent coverage by potential value concentrates heavily in VISN 12 and bulk VISN 20 orders, indicating a divergence between volume (many small orders across many networks) and dollars (large bulk orders from a handful of networks).
Actelion holds two parent indefinite delivery vehicles. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a $438.2 million multiple-award schedule awarded August 1, 2024, and running through July 31, 2029, generated 2,151 delivery orders worth $419.4 million in combined potential value—the primary vehicle driving award activity. A single-award Blanket Purchase Agreement, valued at $118.5 million and awarded August 22, 2024, running through August 21, 2027, covers the same seven-drug portfolio (Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, Opsynvi) and supplements ordering capacity. A predecessor $83.5 million BPA (May 2024–May 2025) and related prior vehicles with similar structures have facilitated recurring procurement. All delivery orders are firm fixed-price with no subcontractor involvement.
Activity has declined year over year, from 48 awards in 2023 to 17 in 2026 (year-to-date through September 2026). The primary NAICS category is Pharmaceutical Preparation Manufacturing (1,930 awards), with the primary PSC category as Drugs and Biologicals (1,760 awards). Actelion competes across 26 distinct federal agencies, though Veterans Affairs and Bureau of Prisons concentration is overwhelming. The combined potential value across all awards is $1.14 billion; combined dollars obligated are $36.9 million, representing 3 percent of combined potential value and reflecting the firm fixed-price, delivery-order nature of the work—orders are scheduled over multi-month performance periods and represent authorization ceilings rather than obligated spend at award.
Quick answers
Is Actelion Pharmaceuticals US, Inc. registered in SAM.gov?
Yes. Actelion Pharmaceuticals US, Inc.'s SAM.gov registration is active through November 20, 2026.
Which contract vehicles does Actelion Pharmaceuticals US, Inc. hold?
Actelion Pharmaceuticals US, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Actelion Pharmaceuticals US, Inc. received in federal contracts?
Federal contracts obligated $1,361,413 to Actelion Pharmaceuticals US, Inc. in fiscal year 2025 and $7,062,717 in fiscal years 2023 through 2027.
How does Actelion Pharmaceuticals US, Inc. rank among federal contractors?
Actelion Pharmaceuticals US, Inc.'s parent company, Janssen Biotech Inc., ranked #46 in PSC Q517, #58 in NAICS 325412 and #91 in NAICS 3254 in FY2025.
What is Actelion Pharmaceuticals US, Inc.'s most recent federal award?
Actelion Pharmaceuticals US, Inc.'s most recent federal contract award is Veletri 1.5MG SDV october FY27 $53.43 x 120 $6411.60 (15B50527F00000004), from Federal Medical Center Carswell (BOP), on October 21, 2026.
On GovTribe
See Actelion Pharmaceuticals US, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors